Galenicum obtains approval for first injectable product

January 3, 2017

The first injectable product in Galenicum’s portfolio has been approved. The systemically-administered antifungal product is indicated for the treatment of candidiasis and invasive aspergillosis. The use of this product is restricted to severe cases due to the high cost of each vial. Galenicum is aiming to make innovative treatments with the highest quality standards more accessible with the launch of this product.

Registration has been attained on 3 continents:

- Europe: Austria, Germany, Greece, Spain, France, Croatia, Italy, the Netherlands, Poland, Portugal, Romania, Sweden and the United Kingdom.

- The Americas: Chile, Peru and Colombia (Mexico coming soon)

- Australia

With this important launch, Galenicum is reinforcing its innovative product portfolio, adding significant value American businesses’ portfolios and has entered the Australian market for the first time.


Homo J gran 2